UBS maintains a 'Neutral' on Arena Pharma (NASDAQ: ARNA), lowers PT from $2 to $1.50.

UBS analyst says, "We note ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE